title: [Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis].
abstract: OBJECTIVE
  Estimate pneumococcal vaccine effectiveness in preventing Streptococcus pneumoniae illness in the elderly.
  
  
  METHODS
  Systematic review and meta-analysis. DATA SOURCE. MEDLINE, years 1964 to the 2000; EMBASE, from 1988 to the 2000; Cochrane Library, identified studies and previously published systematic reviews citations peruse, and contacts with field experts.
  
  
  METHODS
  Clinical trials, cohort and case-control studies, published in Spanish, English or French, that estimated pneumococcal disease rates in vaccinated or not vaccinated elderly.
  
  
  METHODS
  The studies were valued independently by four investigators with predefined criteria of validity, such as results comparing rates of disease caused by serotypes included in the vaccine, random allocation, double blind design, included subjects pertaining to the same study base, and losses of less than 10% in clinical trials and 20% in observational studies.
  
  
  RESULTS
  Eight clinical trials considered the relative risk (RR) of pneumococcal pneumonia, three did not make estimations on pneumonia originated by serotypes included in the vaccine and only one study fulfilled all the inclusion criteria. Vaccinated versus not vaccinated pneumococcal pneumonia RR was 0.86 (95%CI, 0.24 to 2.99). Vaccine effectiveness was 14% (95%CI, -199 to 76%). Ten studies performed estimations on the effectiveness of the vaccine on invasive disease by vaccine serotypes. Of these, two clinical trials and two observational studies fulfilled the required quality criteria. RR of invasive disease was of 0.68 (95%CI, 0.39-1.18); vaccine effectiveness was 32% (95%CI, 18-61%).
  
  
  CONCLUSIONS
  No evidence was found supporting pneumococcal vaccine effectiveness to reduce or avoid S. pneumoniae disease in the elderly.
authors.affiliation: Grupo de Trabajo de Vacunas de la Sociedad Valenciana de Medicina de Familia y Comunitaria (SVMFYC). Promoción de Salud. Centro de Salud Pública de Castellón. Spain. jpuigb@terra.es
authors.forename: J
authors.initials: J
authors.lastname: Puig-Barberà
authors.forename: A
authors.initials: A
authors.lastname: Belenguer Varea
authors.forename: M
authors.initials: M
authors.lastname: Goterris Pinto
authors.forename: M J
authors.initials: MJ
authors.lastname: Brines Benlliure
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology; D011018:Pneumonia, Pneumococcal / Q000517:prevention & control*; D011897:Random Allocation; D012306:Risk
chemical_list: D022242:Pneumococcal Vaccines